These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 18243433)

  • 1. Innate immunity phenotypic features point toward simultaneous raise of activation and modulation events following 17DD live attenuated yellow fever first-time vaccination.
    Martins MA; Silva ML; Elói-Santos SM; Ribeiro JG; Peruhype-Magalhães V; Marciano AP; Homma A; Kroon EG; Teixeira-Carvalho A; Martins-Filho OA
    Vaccine; 2008 Feb; 26(9):1173-84. PubMed ID: 18243433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults.
    Silva ML; Martins MA; Espírito-Santo LR; Campi-Azevedo AC; Silveira-Lemos D; Ribeiro JG; Homma A; Kroon EG; Teixeira-Carvalho A; Elói-Santos SM; Martins-Filho OA
    Vaccine; 2011 Jan; 29(3):583-92. PubMed ID: 20732465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.
    Collaborative Group for Studies with Yellow Fever Vaccine
    Vaccine; 2007 Apr; 25(16):3118-23. PubMed ID: 17316925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development.
    Gaspar LP; Mendes YS; Yamamura AM; Almeida LF; Caride E; Gonçalves RB; Silva JL; Oliveira AC; Galler R; Freire MS
    J Virol Methods; 2008 Jun; 150(1-2):57-62. PubMed ID: 18420285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children.
    Campi-Azevedo AC; de Araújo-Porto LP; Luiza-Silva M; Batista MA; Martins MA; Sathler-Avelar R; da Silveira-Lemos D; Camacho LA; de Menezes Martins R; de Lourdes de Sousa Maia M; Farias RH; da Silva Freire M; Galler R; Homma A; Ribeiro JG; Lemos JA; Auxiliadora-Martins M; Caldas IR; Elói-Santos SM; Teixeira-Carvalho A; Martins-Filho OA
    PLoS One; 2012; 7(12):e49828. PubMed ID: 23251351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination.
    da Costa-Rocha IA; Machado KLLL; Campi-Azevedo AC; Teixeira-Carvalho A; Peruhype-Magalhães V; de Lima SMB; Miranda EH; Trindade GF; Casagrande TZ; Miyamoto ST; Deotti SC; Barbosa RVR; Rocha PCM; Serrano EV; Dinis VG; Gouvêa SA; Gavi MBRO; da Silva LB; Duque RH; Gianordoli APE; Bissoli MF; Gouvea MDPG; Pinto-Neto LFDS; Burian APN; Fantinato FFST; Pileggi GS; da Mota LMH; Valim V; Martins-Filho OA
    Sci Rep; 2021 May; 11(1):10431. PubMed ID: 34001945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TLR expression and NK cell activation after human yellow fever vaccination.
    Neves PC; Matos DC; Marcovistz R; Galler R
    Vaccine; 2009 Sep; 27(41):5543-9. PubMed ID: 19647065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.
    Muyanja E; Ssemaganda A; Ngauv P; Cubas R; Perrin H; Srinivasan D; Canderan G; Lawson B; Kopycinski J; Graham AS; Rowe DK; Smith MJ; Isern S; Michael S; Silvestri G; Vanderford TH; Castro E; Pantaleo G; Singer J; Gillmour J; Kiwanuka N; Nanvubya A; Schmidt C; Birungi J; Cox J; Haddad EK; Kaleebu P; Fast P; Sekaly RP; Trautmann L; Gaucher D
    J Clin Invest; 2014 Jul; 124(7):3147-58. PubMed ID: 24911151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production of yellow fever 17DD vaccine virus in primary culture of chicken embryo fibroblasts: yields, thermo and genetic stability, attenuation and immunogenicity.
    Freire MS; Mann GF; Marchevsky RS; Yamamura AM; Almeida LF; Jabor AV; Malachias JM; Coutinho ES; Galler R
    Vaccine; 2005 Mar; 23(19):2501-12. PubMed ID: 15752837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine signatures of innate and adaptive immunity in 17DD yellow fever vaccinated children and its association with the level of neutralizing antibody.
    Luiza-Silva M; Campi-Azevedo AC; Batista MA; Martins MA; Avelar RS; da Silveira Lemos D; Bastos Camacho LA; de Menezes Martins R; de Lourdes de Sousa Maia M; Guedes Farias RH; da Silva Freire M; Galler R; Homma A; Leite Ribeiro JG; Campos Lemos JA; Auxiliadora-Martins M; Eloi-Santos SM; Teixeira-Carvalho A; Martins-Filho OA
    J Infect Dis; 2011 Sep; 204(6):873-83. PubMed ID: 21849284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?
    Barrett AD; Teuwen DE
    Curr Opin Immunol; 2009 Jun; 21(3):308-13. PubMed ID: 19520559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children.
    Campi-Azevedo AC; Reis LR; Peruhype-Magalhães V; Coelho-Dos-Reis JG; Antonelli LR; Fonseca CT; Costa-Pereira C; Souza-Fagundes EM; da Costa-Rocha IA; Mambrini JVM; Lemos JAC; Ribeiro JGL; Caldas IR; Camacho LAB; Maia MLS; de Noronha TG; de Lima SMB; Simões M; Freire MDS; Martins RM; Homma A; Tauil PL; Vasconcelos PFC; Romano APM; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA
    Front Immunol; 2019; 10():2192. PubMed ID: 31616412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viscerotropic disease following yellow fever vaccination in Peru.
    Whittembury A; Ramirez G; Hernández H; Ropero AM; Waterman S; Ticona M; Brinton M; Uchuya J; Gershman M; Toledo W; Staples E; Campos C; Martínez M; Chang GJ; Cabezas C; Lanciotti R; Zaki S; Montgomery JM; Monath T; Hayes E
    Vaccine; 2009 Oct; 27(43):5974-81. PubMed ID: 19679215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 17DD Yellow Fever Revaccination and Heightened Long-Term Immunity in Populations of Disease-Endemic Areas, Brazil.
    Campi-Azevedo AC; Peruhype-Magalhāes V; Coelho-Dos-Reis JG; Antonelli LR; Costa-Pereira C; Speziali E; Reis LR; Lemos JA; Ribeiro JGL; Bastos Camacho LA; de Sousa Maia ML; Barbosa de Lima SM; Simões M; de Menezes Martins R; Homma A; Cota Malaquias LC; Tauil PL; Costa Vasconcelos PF; Martins Romano AP; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA;
    Emerg Infect Dis; 2019 Aug; 25(8):1511-1521. PubMed ID: 31298654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The early cellular signatures of protective immunity induced by live viral vaccination.
    Kohler S; Bethke N; Böthe M; Sommerick S; Frentsch M; Romagnani C; Niedrig M; Thiel A
    Eur J Immunol; 2012 Sep; 42(9):2363-73. PubMed ID: 22733156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization?
    Martins MA; Silva ML; Marciano AP; Peruhype-Magalhães V; Eloi-Santos SM; Ribeiro jG; Correa-Oliveira R; Homma A; Kroon EG; Teixeira-Carvalho A; Martins-Filho OA
    Clin Exp Immunol; 2007 Apr; 148(1):90-100. PubMed ID: 17309541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Booster dose after 10 years is recommended following 17DD-YF primary vaccination.
    Campi-Azevedo AC; Costa-Pereira C; Antonelli LR; Fonseca CT; Teixeira-Carvalho A; Villela-Rezende G; Santos RA; Batista MA; Campos FM; Pacheco-Porto L; Melo Júnior OA; Hossell DM; Coelho-dos-Reis JG; Peruhype-Magalhães V; Costa-Silva MF; de Oliveira JG; Farias RH; Noronha TG; Lemos JA; von Doellinger Vdos R; Simões M; de Souza MM; Malaquias LC; Persi HR; Pereira JM; Martins JA; Dornelas-Ribeiro M; Vinhas Ade A; Alves TR; Maia Mde L; Freire Mda S; Martins Rde M; Homma A; Romano AP; Domingues CM; Tauil PL; Vasconcelos PF; Rios M; Caldas IR; Camacho LA; Martins-Filho OA
    Hum Vaccin Immunother; 2016; 12(2):491-502. PubMed ID: 26360663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of the risks and benefits of yellow fever vaccination including some new analyses.
    Monath TP
    Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 17D-204 and 17DD yellow fever vaccines: an overview of major similarities and subtle differences.
    Ferreira CC; Campi-Azevedo AC; Peruhype-Magalhāes V; Costa-Pereira C; Albuquerque CP; Muniz LF; Yokoy de Souza T; Oliveira ACV; Martins-Filho OA; da Mota LMH
    Expert Rev Vaccines; 2018 Jan; 17(1):79-90. PubMed ID: 29172832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response.
    Blom K; Braun M; Ivarsson MA; Gonzalez VD; Falconer K; Moll M; Ljunggren HG; Michaëlsson J; Sandberg JK
    J Immunol; 2013 Mar; 190(5):2150-8. PubMed ID: 23338234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.